Victor Van de Wiele

Solve Intelligence works with over 700+ patent teams as they bring AI into daily practice, and the same pattern shows up again and again: recognising that AI helps is easy, but building consistent, team-wide use is not. Adoption tends to stall for a handful of reasons, from informal early experiments to unclear decision making, and a promising trial can fade out without anyone establishing whether the tool or the rollout was at fault. This playbook lays out the process that gets a team from first experiment to settled habit, with the attorney's judgment in control at every step.

Generic and biosimilar IP teams are already using AI for prosecution history and FTO work. The live debate is not about adoption, but internal framing of quality and coverage extension without reducing headcount. The teams furthest along chose the former.

Key Takeaways:

• Generic and biosimilar IP teams use AI primarily for prosecution history summaries, invalidity analysis and FTO claim charting.
• Viewing AI as a quality and coverage extension drives durable internal adoption.
• General-purpose AI cannot reliably interpret claim scope from prosecution history; patent-specific tools are required.